NICE has recommended a new treatment option for women with recurrent or metastatic cervical cancer, saying it will now be available on the NHS after final draft guidance published on 24 June 2026. The decision adds another oncology option to the UK care pathway for a disease that has come back or spread to other parts of the body.
A new NHS option for a difficult-to-treat cancer
According to NICE, the recommendation covers cervical cancer that has returned or advanced beyond its original site. The organisation said the treatment is now available on the NHS following the publication of its final draft guidance, marking a significant development for patients with limited options. ([nice.org.uk](https://www.nice.org.uk/news/articles))
The announcement comes amid a run of recent cancer-related decisions from NICE, including guidance on ovarian cancer and stomach cancer, but this latest update is focused specifically on recurrent or metastatic cervical cancer. ([nice.org.uk](https://www.nice.org.uk/news/articles))
What NICE said in its latest update
NICE listed the decision in its news articles page on 24 June 2026, describing it as a new treatment option that is now available on the NHS. The organisation’s cervical cancer topic page also shows that there has been a recent addition in the last six months, indicating continued activity in this disease area. ([nice.org.uk](https://www.nice.org.uk/news/articles))
The update is relevant for the UK because NICE guidance often determines whether new medicines and technologies are adopted across the NHS. In this case, the recommendation creates a new route for treatment in a setting where disease control is often more challenging once cancer has spread or recurred. ([nice.org.uk](https://www.nice.org.uk/news/articles))
Why the decision matters for patients
Recurrent or metastatic cervical cancer is typically harder to manage than earlier-stage disease, so any additional NHS-backed option can matter for both treatment choice and clinical planning. NICE’s announcement does not provide detailed efficacy figures in the short news listing, but it does confirm that the therapy has progressed through the appraisal process and has now reached final draft guidance. ([nice.org.uk](https://www.nice.org.uk/news/articles))
The decision also reflects a broader pattern in recent NICE activity, with several high-impact cancer treatments being assessed or recommended in quick succession. For clinicians and patients, that can mean more options become available closer to the time they are needed, rather than later in the disease journey. ([nice.org.uk](https://www.nice.org.uk/news/articles))
As NICE continues to publish new cancer guidance, the latest cervical cancer recommendation stands out as another example of how the NHS can broaden access to treatments for difficult-to-treat disease. Further implementation details are expected to follow through the usual NICE and NHS pathways. ([nice.org.uk](https://www.nice.org.uk/news/articles))
